Contents
Special Issue Topic

Endocrine Resistant Breast Cancer

Guest Editors

Dr. Simon Langdon E-Mail

Reader, School of Medicine, University of Edinburgh, Edinburgh, UK

Research Keywords: ovarian cancer; breast cancer; estrogen signaling; HER signaling; DNA repair

Dr. Valerie Speirs E-Mail

Professor and Chair in Molecular Oncology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK

Research Keywords: oestrogen receptor biology; endocrine resistant breast cancer; male breast cancer; in vitro models; biomarker

About the Special lssue

The majority of breast cancers are estrogen receptor alpha (ERa) positive and most will initially respond to endocrine therapy. Current therapies to treat ERa-positive disease include aromatase inhibitors, selective estrogen receptor modulators (SERMs) and selective estrogen down-regulators (SERDs). However, resistance to these treatments will develop in many cancers and can be present either at the outset (de novo resistance) or develop on treatment (acquired resistance). Experimental and clinical investigations have demonstrated multiple mechanisms that can give rise to resistance and a range of therapeutic agents such as CDK4/6 inhibitors and other signalling inhibitors have been developed to circumvent these. Resistance mechanisms include changes in ER status (e.g. loss and mutation) and the involvement of compensatory pathways bypassing the dependence on estrogen activation particularly growth factor activation.

In this issue, we welcome Reviews and Original Articles encompassing experimental laboratory research studies of endocrine resistance through to clinical investigations in breast cancer.

Keywords: Breast cancer; resistance; endocrine; estrogen

Published Articles

Open Access Review
Endocrine therapy resistance: what we know and future directions
David Musheyev, Anya Alayev
Published: August 31, 2022 Explor Target Antitumor Ther. 2022;3:480–496
3097 46 7
Open Access Review
Exploring new pathways in endocrine-resistant breast cancer
Inês Soares de Pinho ... Luís Costa
Published: June 20, 2022 Explor Target Antitumor Ther. 2022;3:337–361
3043 50 2
Open Access Review
In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy
Gary J. Cheng ... Dean C. Singleton
Published: June 01, 2022 Explor Target Antitumor Ther. 2022;3:297–320
3869 102 6
Open Access Perspective
Endocrine resistant breast cancer: brain metastasis
Matthew Willman ... Brandon Lucke-Wold
Published: April 26, 2022 Explor Target Antitumor Ther. 2022;3:240–251
2714 44 9
Open Access Original Article
The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer
Samuel Jones ... Kathryn M. Taylor
Published: April 26, 2022 Explor Target Antitumor Ther. 2022;3:224–239
3503 87 2
Open Access Review
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
Aglaia Skolariki ... Simon Lord
Published: April 24, 2022 Explor Target Antitumor Ther. 2022;3:172–199
4562 101 14
Open Access Original Article
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
Kate M. Moore ... Simon P. Langdon
Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:97–116
2448 70 1
Open Access Review
Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
Alfredo Rossi ... Marta Carlesimo
Published: October 31, 2021 Explor Target Antitumor Ther. 2021;2:490–495
2584 38 3
Open Access Review
Role of estrogen receptor coregulators in endocrine resistant breast cancer
Kristin A. Altwegg, Ratna K. Vadlamudi
Published: August 30, 2021 Explor Target Antitumor Ther. 2021;2:385–400
4786 107 17